stock poised for growth amid obesity market potential By Investing.com
Amgen Inc . (NASDAQ:), a leading biopharmaceutical company, is navigating a critical juncture in its growth trajectory as it focuses on expanding its presence in the lucrative obesity treatment market while maintaining its strong position in established therapeutic areas. With a market capitalization of $140.06 billion and impressive revenue growth of 21.25% over the last twelve months, Amgen continues to attract investor attention due to its robust product pipeline and strategic initiatives. According to InvestingPro analysis, the company maintains a strong financial profile with consistent profitability and a notable 3.58% dividend yield.
Recent Financial Performance and Market Position
Amgen reported in-line revenues and non-GAAP…
